• Abstract submissions will be considered for lecture or poster presentation during Congress sessions taking place Jan. 22-24, 2026, at the Bellagio Las Vegas.
• Abstracts must be submitted online through the abstract submission portal by the submission deadline. No faxed, emailed or mailed abstracts will be accepted.
• There is no fee to submit an abstract.
• Authors do not have to be a member of the sponsoring organizations to submit an abstract. 
• The submitter does not have to be the primary author or presenter.
• Submissions from international attendees and trainees are welcome and encouraged.

• Abstracts containing basic, clinical, or translational research findings in the field of IBD may be submitted.
• NEW FOR 2026: Abstracts that have been submitted to or presented at other national or international meetings may be submitted provided that prior presentation and/or submission to other meetings is declared during the Congress submission process.
• Abstracts that have been previously published as an article or full paper at the Sept. 24 submission deadline will not be considered for presentation and should not be submitted.
• Contact info@crohnscolitiscongress.org if you have any questions about abstract eligibility.

• Presenting authors will receive an email on Thursday, Sept. 25, 2025, with a link to the Congress financial disclosure site.
• After accessing their account at the site, presenters must list their relationships with ineligible companies held over the past 24 months or indicate that no relationships exist.
  • Presenters with relationships must indicate the name of the ineligible company and also the type of relationship held (e.g., owner, research grant, shareholder, employee, board member, consultant, etc.).
• The deadline for presenters to submit their disclosure is 5 p.m. EDT on Friday, Oct. 3, 2025.
• Abstracts missing presenter disclosure at the disclosure deadline may be withdrawn from consideration for presentation at the Congress.
• Co-authors will not receive email regarding financial disclosure, as only presenters are asked to submit.

• Presenting authors of abstracts accepted for presentation are required to register for and attend the Crohn’s & Colitis Congress to present their abstract in person at the date and time specified in their acceptance invitation.
  • Virtual presentations (e.g., pre-recorded videos or live streams) will not be permitted.
• Abstract acceptance notifications will be sent to presenting authors on Monday, Nov. 17, 2025.

• The deadline to accept the invitation to present the abstract is 5 p.m. EDT on Friday, Nov. 21, 2025.
  • Failure to accept the invitation to present by the deadline will result in the automatic withdrawal of the abstract from the Congress program.
• Presenting authors of abstract accepted for presentation at the Congress are required to register for the Congress by 5 p.m. EST on Wednesday, Dec. 9, 2025, which is the final day to receive discounted registration rates.
  • Failure by the presenter to register by Dec. 9 will result in the automatic withdrawal of the abstract from the Congress program.
• The presenting author of an abstract can be changed provided that the new presenter was listed as an author on the abstract at the time of submission and that the new presenter is registered for the meeting at the time of the change request.
  • If no authors are able to register for and attend the meeting, the abstract will be withdrawn.
  • Presenter changes will be accepted beginning on Oct. 1, 2025. Prior to October, contact info@crohnscolitiscongress.org with any questions. 

When submitting an abstract, authors must select one of the following categories that aligns with their science:

Clinical Science Submission Categories

• Adverse Events Related to Therapy
• Comparative Effectiveness Studies
• Controlled Clinical Trials in Humans
• Diagnostics in IBD
• Disease Activity Assessment and Monitoring
• Disease Complications
• Epidemiology and Environmental Determinants
• Health Care Delivery and Policy (Practice Management Including Telehealth‚ Reimbursement‚ Access to Care)
• Health Care Quality and Delivery
• Health Disparities in Patients with GI Disease
• IBD in Special Populations: Conception, Adolescence, and Older Adults
• Issues of Diversity and Inclusion in GI Healthcare Delivery and Education
• Microscopic Colitis, Drug-Induced, and Other Enterocolitides
• Natural History and Longitudinal Disease Outcomes
• Nutrition and IBD
• Pediatric IBD: Clinical and Translational Studies
• Quality of Life and Psychosocial Outcomes
• Therapeutic Drug Monitoring
• Uncontrolled Therapeutic Observations: Biologics
• Uncontrolled Therapeutic Observations: Non-Biologics

Basic Science Submission Categories

• Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation
• Cytokines, Signaling and Receptors
• Genetics, Epigenetics, and Gene Function
• Immune Cells in Intestinal Inflammation
• Inflammatory Bowel Disease: Mucosal Innate Function, Host Defense
• Intestinal Inflammation—Cell Signaling, Injury, Repair and Fibrosis
• Microbiome Role in Intestinal Inflammation
• Neuroimmune Interactions
• Non-Immune Cells in Intestinal Inflammation
• Omics for Diagnosis, Disease Stratification and Therapy Selection
• Role of Fungi, Viruses and Phages in GI Diseases
• Role of the Gut Microbiome and Pathogens in Immune and Inflammatory Diseases
• Translational Application of Intestinal Stem Cells and Organoid Models

Authors can choose one topic only for each abstract submitted. If an abstract fits into more than one submission category, the submitter should choose the most appropriate one, as abstracts may be submitted only one time to a single category.

• Abstract titles may not exceed 255 characters, including spaces. Please refrain from using commercial names, institution names, non-standard abbreviations or author names in the title.
• All abstract titles must be capitalized. The use of superscript, subscript and special characters in abstract titles is permitted.
• There is a limit of 2,900 characters, including spaces, for the abstract text. Information included in images submitted as part of the abstract does not count toward this limit.
• Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases.
• Authors are not required to use headings in their abstracts. If used, however, headings will count toward the 2900 character limit.
• Drug products mentioned in abstracts should be identified by their nonproprietary (i.e., generic) names only.
• Authors may submit up to two images per abstract. Images are not required.
  • Images will only be accepted in .bmp, .gif, .jpg., .png, or .tif file types. PDFs will not be accepted.
  • Images may not exceed 2 GB in size.
  • For assistance taking a screen shot of a Word, Excel or PowerPoint table and saving as an image, follow these instructions on taking a screen shot using Windows or using a Mac.
  • Please format your images appropriately, as images will be published as submitted if accepted for presentation. Be sure to remove any large white borders from images. Large images may be scaled for publication.

Submitted abstracts may be edited any time prior to the Sept. 24 submission deadline. To edit an abstract, make the needed changes under the appropriate tasks at the submission site. Edited abstracts must then be saved and resubmitted by the submission deadline. 

• The deadline to submit an abstract for consideration for the 2025 meeting is 9 p.m. EDT on Wednesday, Sept. 24, 2025. Absolutely no changes to abstracts or author strings will be permitted after this deadline.
• The submitter certifies that they have the right to submit the abstract and that the data included in the abstract submission and/or presented at the Crohn’s & Colitis Congress is truthful, original, unduplicated and without fraud or fabrication.
• The submitter certifies all authors listed in the submission are investigators with substantial involvement in the study presented in the abstract.
• By submitting an abstract, the submitting author confirms that he or she has permission from all co-authors to include their names in the submission and that all co-authors are aware of and agree to the content of the abstract and support the data contained therein. Submitting authors may, upon request by Congress administration, be asked to provide proof that all authors have given permission for the submission of the abstract and agree on its content.
• The submitter accepts responsibility for the accuracy of the original data and scientific content of the submitted abstract. Please proofread the abstract carefully prior to submission, as edits to the abstract or author string will not be permitted after the Sept. 24 submission deadline.
• The submitter confirms that the submitted abstract has not been previously published as an article or full paper as of the submission deadline.
• The submitter confirms that the abstract has not been submitted to more than one category or submitted by a co-author.
• The submitter confirms that copyright permissions for all third-party material (including and without limitation textual extracts or illustrations, photographs, maps, diagrams and tables) have been obtained.
• U.S. Government employee authors: The corresponding author warrants that the work was authored by employees of the U.S. government as part of their official duties and therefore may be published and reproduced without restriction.
• Abstracts that include clinical trial data should follow the CONSORT statement.
• Any human experimentation conducted conforms with the principles of the Declaration of Helsinki of the  World Medical Association, and meets all the requirements governing informed consent of the country in which the research was performed.
• Any animal studies should conform with the October 2014 revision of The Guiding Principles in the Care and Use of Vertebrate Animals in Research and Training by the American Physiological Society
• By submitting an abstract, the submitter accepts responsibility as the contact person for all correspondence about the abstract and will inform co-authors about its status. Only submitters and presenters will receive email from the Congress regarding abstract submission; co-authors will not receive email correspondence from the Congress regarding abstract acceptance status.
• Presenting authors listed on an abstract are required to submit financial disclosure at the Congress disclosure site by disclosing relationships with ineligible companies by 5 p.m. EDT on Oct. 3, 2025.

• Abstract acceptance notifications will be sent to presenting authors on Nov. 17, 2025.
  • Presenting authors must affirmatively accept their invitation to present by 5 p.m. EST on Nov. 21, 2025.
  • If an invitation is declined, the abstract will be removed from the Congress agenda.
  • Failure to respond to an invitation to present will result in removal of the abstract from the Congress program.
• Submission of an abstract constitutes a formal commitment by the presenting author to present the abstract in person in Las Vegas in the session and at the time decided upon by the Congress Organizing Committee.
  • Virtual presentations will not be permitted.
  • Presenters of abstracts accepted for presentation at the 2026 Congress are required to register for the meeting by 5 p.m. EST on Wednesday, Dec. 9, 2025, which is the final day to receive discounted registration rates.
  • Failure by the presenter to register by Dec. 9 will result in the automatic withdrawal of the abstract from the Congress program.
• Presenter changes are subject to the following policies:
  • Presenter changes will be accepted beginning on Oct. 1, 2025, and must be made in writing.
  • Abstracts may be presented only by authors listed in the author string as of the submission deadline.
  • If an invitation to present an abstract has already been accepted at the time of the presenter change request, the new presenter must be registered for the Congress in order for the change to be made.
  • Presenters must pay the applicable registration rate available on the day they register. Previously available rates or discounts cannot be honored.
  • Registrations cannot be transferred between abstract authors.
• If an invitation to present an abstract has been accepted, failure to present it onsite in Las Vegas could lead to rejection of abstracts submitted to future Crohn’s & Colitis Congress meetings.
• All presentations will be in English. Oral abstract presentations must be made by an author who speaks and understands English.
• Any expenses associated with the submission and presentation of an abstract are the sole responsibility of the authors.
• If selected for presentation, the copyright of the abstract is released to the Crohn’s & Colitis Foundation and AGA for publication in any and all Congress materials, including but not limited to online supplements to Gastroenterology and Inflammatory Bowel Diseases as well as inclusion at the Congress website, mobile application and/or any other official Congress publications.
• Authors whose abstracts are selected for lecture presentation are advised that Congress sessions may be recorded and made available to in-person and virtual attendees as on-demand video content.

All data presented at Crohn’s & Colitis Congress is embargoed until 8 a.m. PST on the first day of the Congress, Thursday, Jan. 22, 2026.

Abstracts may be made available online to attendees in advance of the Congress for itinerary planning purposes. The embargo policy applies to all abstract data regardless of the date of publication in Congress resources.

Prior to the Sept. 24 submission deadline, submitters may withdraw submitted abstracts at the submission site. After logging in, submitters should navigate to the abstract task list and then click on the abstract title. Next, using the “Select Status” dropdown, select “Withdrawn.” Finally, click “Save” to withdraw the abstract.

After the submission deadline, the Congress will withdraw abstracts upon written notification to info@crohnscolitiscongress.org from the submitting author. Requests to withdraw abstracts should be made by 5 p.m. EST on Dec. 8, 2025. After this date, the Congress cannot guarantee that a withdrawn abstract will be excluded from publication. 

1. Read the full abstract submission guidelines.
2. Compose your abstract, ensuring that your abstract adheres to published character count limitations and formatting.
3. Upload up to two images (optional).
4. List all co-authors.
5. Review and proof abstract.
6. Finalize abstract and submit online by 9 p.m. EDT on Sept. 24, 2025.
7. Ensure that the presenting author completes their financial disclosure by 5 p.m. EDT on Oct. 3, 2025.
8. Ensure the presenting author checks their email on Nov. 17 for an abstract decision email.

For abstract-related inquiries, please contact info@crohnscolitiscongress.org